Tecentriq

Active substance

Atezolizumab

Holder

Roche

Status

Closed

Indication

Treatment of first line for adult patients with locally advanced or metastatic, positive PD-L1, triple negative breast cancer, in combination with nab-paclitaxel.

Public documents

Approbation

Information for the patient

Informed consent

Last update

01/04/2021